Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The two-dose protein-based vaccine, branded Nuvaxovid, is the fifth coronavirus vaccine recommended by the EU.

Novavax Climbs as Its Covid Vaccine Recommended for EU Approval

The European Medicines Agency, the regulator for the European Union, has recommended granting a conditional marketing authorization to the COVID-19 vaccine developed by Novavax Inc. NVAX, +11.49% to prevent the illness in people aged 18 and older. The vaccine called Nufaxovid is now the fifth recommended in the EU for preventing COVID.

EU regulator backs authorization for Novavax COVID-19 vaccine, sending stock up 10% premarket

European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for Novavax' COVID-19 vaccine (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age and older.

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by over 9% pre-market today. This is why it happened.

Novavax Stock (NVAX): Why The Price Jumped Today

New York, New York--(Newsfile Corp. - December 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Rosen, A Leading Law Firm, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Zoom Video

Zoom and Novavax remain well below their pandemic-era peaks.

Is the Omicron Surge Helping These 2 Nasdaq Stocks Recover?

The World Health Organization issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine. The vaccine, named Covovax, is produced by the Serum Institute of India and is part of the COVAX facility portfolio.

WHO Issues Emergency Use Listing to Novavax-Serum Institute's COVID-19 Vaccine

The authorization could pave the way for the vaccine to be distributed in more countries.

WHO Grants Novavax Covid Vaccine Emergency Use Approval As Omicron Fears Deepen

LOS ANGELES, Dec. 17, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX). Class Period: March 2, 2021 – October 19, 2021 Lead Plaintiff Deadline: January 11, 2022 If you wish to serve as lead plaintiff of the Novavax lawsuit, you can submit your contact information at www.glancylaw.com/cases/novavax-inc/.

NVAX Investors Have Opportunity to Lead Novavax, Inc. Securities Fraud Lawsuit

Novavax Inc. (NASDAQ:NVAX) shares were trading higher Friday after the World Health Organization issued emergency use listing for its NVX-CoV2373 COVID-19 vaccine. The stock is trading higher and saw a push toward a resistance level in the pattern in which it trades.

Novavax Stock Pushes Higher In A Pattern: Technical Analysis

The vaccine maker and the Serum Institute of India were issued an emergency use authorization for their Covid-19 vaccine by the World Health Organization.

Novavax Covid Vaccine Gets Emergency-Use Approval From WHO

The World Health Organization granted Emergency Use Listing to its COVID-19 vaccine.

Why Novavax Stock Is Jumping Again Today

Today, the WHO approved emergency use listing for Novavax's vaccine, Covovax. NVAX stock is popping today as a result.

NVAX Stock Pops as the WHO Grants Novavax's Vaccine Emergency Use. 8 Things to Know.

First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

AbbVie

Calliditas Therapeutics AB

Pfizer

Valneva SE

Should investors be treating these top biotech stocks as top picks in the stock market now?

5 Biotech Stocks For Your Late December 2021 Watchlist

BioNTech SE

Moderna

All of these vaccine stocks benefited from rising concerns about the Omicron variant.

Why Novavax, BioNTech, and Moderna Stocks Are Jumping This Week

Novavax is waiting on good news from the World Health Organization. An EUA would push it above $200.

While Novavax Stock Remains Cursed, It Might Be Time to Buy

Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd (NYSE: TAK). The protein-based COVID-19 vaccine includes Matrix-M adjuvant and is known as TAK-019 in Japan and NVX-CoV2373 outside Japan.

Novavax Files For Approval Of Its COVID-19 Vaccine In Japan

Up until March 2020, Novavax was pretty much an unknown, obscure drug research outfit developing vaccines for diseases such as Ebola.

Novavax: Looking At A Monster Rise In Revenues In 2022

GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for its COVID-19 vaccine by its partner Takeda Pharmaceutical Company Limited (Takeda).

Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine

Radnor, Pennsylvania--(Newsfile Corp. - December 15, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Novavax, Inc.

San Francisco, California--(Newsfile Corp. - December 15, 2021) -  Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now.Class Period: Mar. 2, 2021 - Oct. 19, 2021Lead Plaintiff Deadline: Jan. 11, 2022Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com 844-916-0895Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Novavax (NVAX) Investors to Lead Plaintiff Opportunity in Securities Class Action, Encourages Investors with Losses to Contact Firm's Attorneys

The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd generation vaccine candidate.

COVID-19 Vaccines: The Big Omicron Reboot For BioNTech, Moderna And Novavax

NVAX stock is up in the air today ahead of an important WHO meeting to discuss approval of Novavax's vaccine EUA. Here's what to know.

NVAX Stock Is on Watch Ahead of WHO Meeting. Here's What to Know.

Boston, Massachusetts--(Newsfile Corp. - December 15, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

News for Novavax Stock (NVAX)